These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36400657)

  • 1. Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Díaz-Pérez D; Mateos-Dominguez M; Galindo-Jara P
    Eur J Surg Oncol; 2023 Feb; 49(2):323-328. PubMed ID: 36400657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H/dMMR rectal cancer: A prospective, multicenter, phase Ib study.
    Li X; Fang C; Wang X; Yu Y; Wang Z; Qiu M
    Cancer Med; 2022 Dec; 11(23):4405-4410. PubMed ID: 35352512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer.
    Deng Z; Luo Y; Chen X; Pan T; Rui Y; Hu H; Yan J; Zhang K; Luo C; Song B
    Front Immunol; 2024; 15():1466497. PubMed ID: 39399495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
    Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
    Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment.
    Yu JH; Liao LE; Xiao BY; Zhang X; Wu AW; Cheng Y; Tang JH; Jiang W; Kong LH; Han K; Mei WJ; Hong ZG; Yang WJ; Li DD; Pan ZZ; Li YF; Zhang XS; Ding PR
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38498975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
    Yang R; Wu T; Yu J; Cai X; Li G; Li X; Huang W; Zhang Y; Wang Y; Yang X; Ren Y; Hu R; Feng Q; Ding P; Zhang X; Li Y
    Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
    Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
    Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant immunotherapy for colorectal cancer].
    Pei JP; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
    Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
    Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study.
    Wang QX; Xiao BY; Cheng Y; Wu AW; Zhang T; Wang H; Zhang X; Huang WX; Tang JH; Jiang W; Steele SR; Krishnamurthi S; Li Y; Cai J; Kong LH; Li DD; Pan ZZ; Zhang XS; Ding PR
    Eur J Cancer; 2022 Oct; 174():176-184. PubMed ID: 36030556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer.
    Li Y; Zhang W; Du J; Hu J; Hu R; Zeng Z; Jin-Si-Han EE; Lian S; Wang H; Li Y; Pan Z; Feng C; Zhang X; Lu Z
    Target Oncol; 2024 Jul; 19(4):601-610. PubMed ID: 38691294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.
    Liu DX; Li DD; He W; Ke CF; Jiang W; Tang JH; Kong LH; Li Y; Sui QQ; Xiao BY; Li WR; Hong ZG; Xu RH; Pan ZZ; Zhang XS; Ding PR
    Oncoimmunology; 2020; 9(1):1711650. PubMed ID: 32042474
    [No Abstract]   [Full Text] [Related]  

  • 20. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
    Zhang JW; Deng YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.